UNSPSC 51383312: Diclofenac epolamine

This classification denotes a cyclooxygenase inhibitor C14H11Cl2NO2.C6H13NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X5F8EKL9ZG, chemically known as benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)-, compd. with 1-pyrrolidineethanol (1:1), but more generally known as diclofenac epolamine, which bears US NIH Compound Identifier 114753. European Medicines Agency schedules Diclofenac epolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20558.

Most nations, for tariff and trade purposes, schedule diclofenac epolamine under HS 29224995 and SITC 51465. As of Q4 2014, DICLOFENAC EPOLAMINE remains US FDA's Preferred Term for this commodity. Diclofenac epolamine bears US NLM identifiers UMLS ID C0082274 and NCI Concept Code C77355. SMILES: C1CCC(C(C1)CC(=O)O)NC2C(CCCC2CL)CL.C1CCN(C1)CCO.

UNSPSC 51383312 Diclofenac epolamine (Commodity) shows minimal recent state and local procurement activity aligned with the code's nominal scope. The three most-recent opportunities posted under this code involve naloxone and drug deactivation systems, a therapeutic pharmacy initiative, and generic multi-source pharmaceuticals and OTC products — none of which are diclofenac epolamine, a topical nonsteroidal anti-inflammatory drug. The mismatch between the code designation and actual procurement scope suggests either miscategorization in the source data or that state and local governments are not actively soliciting diclofenac epolamine as a standalone commodity at present. When opportunities do appear under this code, they reflect broader pharmaceutical procurement frameworks rather than demand for this specific pharmaceutical agent.

The recent opportunities that carry this code designation originate from diverse issuing bodies: Seminole County, Florida (a county health authority), the Texas Health and Human Services Commission (a state department), and the Minnesota Multistate Cooperative Purchasing Alliance (a multi-state cooperative serving state and local facilities including Oregon). Activity is concentrated in the South and Upper Midwest. The Seminole County naloxone solicitation (IFB 60459723LAS, due July 26, 2023) sought 1,900 annual units through competitive bid. The Texas HHS Commission issued an RFI (HHS0017013, closed April 3, 2026) to gather vendor intelligence on direct-to-manufacturer prescription programs. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) established multi-state contracts for generic pharmaceuticals and OTC products through authorized wholesalers, effective July 1, 2026. None of these solicitations specifically named or prioritized diclofenac epolamine, indicating the code captures pharmaceutical procurement at a higher taxonomic level than this commodity's actual market activity in state and local contracting.